Feed RDY
RD

Dr. Reddy's Laboratories

RDY · NYSE

$12.41 +1.80% (+$0.22)
1M +1.47%
Market Cap ₹990.3B
P/E Ratio 29.86x
Div. Yield 0.67%
ROE 8.94%

Bulios Fair Price

$12.2

1.7% downside

Trenutna cena

$12.41

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price se delnica RDY trenutno trguje blizu svoje poštene vrednosti. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
5/9
Valuation
27 /100
Expensive
P/FCF 65.39x
P/E 29.86x
P/B 2.58x
Growth
86 /100
Growing
FCF growth 9.92%
EPS growth 33.72%
Book val. growth 20.50%
Profitability
57 /100
Moderate
Op. margin 10.57%
Gross margin 50.15%
FCF margin 4.55%
Quality
40 /100
Average
ROA 5.77%
ROIC 5.83%
Asset turnover 0.58x
Debt
91 /100
Low
Int. coverage 9.50x
Debt/Equity 0.19x
Net debt/EBITDA 1.09x
Stability
61 /100
Moderate
EPS volatility 46.77%
Beta 0.25x
Profitable years 6

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RDY
Online

O podjetju

Dr. Reddy's Laboratories Limited (RDY) is an Indian pharmaceutical company specializing in the manufacturing and distribution of a wide range of medicines and generic pharmaceutical products. The company focuses on developing and producing high-quality and affordable medications for patients worldwide. Dr. Reddy's Laboratories has an extensive portfolio of products, including medicines for various therapeutic areas, such as cardiovascular, gastrointestinal, oncology, neurological, and other indications. The company is one of the leading generic pharmaceutical companies and has a strong global presence. Dr. Reddy's Laboratories invests in research and development of new pharmaceutical products and continuously expands its portfolio. Its medications comply with strict quality standards and regulations, making it a trustworthy partner for healthcare institutions, physicians, and patients. Investing in shares of Dr. Reddy's Laboratories Limited (RDY) could present an intriguing opportunity for those who believe in the growing demand for affordable and high-quality generic medicines and the long-term potential of the pharmaceutical industry.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Erez Israeli

Employees

27,527

Headquarters

Hyderabad

Prihajajoči dogodki

23 OKT.

Earnings

Upcoming earnings report

31d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.